Am J Physiol Cell Physiol Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Cell Physiol 291: C1208-C1212, 2006. First published August 2, 2006; doi:10.1152/ajpcell.00226.2006
0363-6143/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/C1208    most recent
00226.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dirks, A. J.
Right arrow Articles by Jones, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dirks, A. J.
Right arrow Articles by Jones, K. M.

MITOCHONDRIAL MODELING AND FUNCTION

Statin-induced apoptosis and skeletal myopathy

Amie J. Dirks and Kimberly M. Jones

Wingate University School of Pharmacy, Wingate, North Carolina

Submitted 1 May 2006 ; accepted in final form 26 July 2006


   ABSTRACT
TOP
 ABSTRACT
CELLULAR PROCESSES OF APOPTOSIS
 STATIN-INDUCED APOPTOSIS
 REFERENCES
 
Over 100 million prescriptions were filled for statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) in 2004. Statins were originally developed to lower plasma cholesterol in patients with hypercholesterolemia and are the most effective drugs on the market in doing so. Because of the discovered pleiotropic effects of statins, the use has expanded to the treatment of many other conditions, including ventricular arrythmias, idiopathic dilated cardiomyopathy, cancer, osteoporosis, and diabetes. The elderly population is growing. Therefore, it is estimated that the number of statin users will also increase. Fortunately, the use of statins is relatively safe with few side effects. Myopathy is the most common side effect with symptoms ranging from fatigue, weakness, and pain to symptoms associated with rhabdomyolysis which is a life-threatening condition. The development of statin-induced rhabdomyolysis is rare occurring in ~0.1% of patients; however, the occurrence of less severe symptoms is underreported and may be 1–5% or more. Physical exercise appears to increase the likelihood for the development of myopathy in patients taking statins. It is thought that as many as 25% of statin users who exercise may experience muscle fatigue, weakness, aches, and cramping due to statin therapy and potentially dismissed by the patient and physician. The mechanisms causing statin-induced myopathy have not been elucidated; however, research efforts suggest that apoptosis of myofibers may contribute. The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptosis will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.

skeletal muscle; 3-hydroxy-3-methylglutaryl coenzyme A; reductase inhibitors; cell death

3-HYDROXY-3-METHYLGLUTARYL coenzyme A (HMG-CoA) reductase inhibitors, known as statins, block the rate-limiting step in de novo cholesterol biosynthesis (see Fig. 1). Statins are most commonly used for the treatment of hyperlipidemias and are the most effective lipid-lowering drugs on the market. Furthermore, statins have been shown to exhibit pleiotropic cellular effects and may have potential uses in the treatment of many other conditions, including ventricular arrythmias, peripheral arterial disease, idiopathic dilated cardiomyopathy, cancer, osteoporosis, diabetes, and depression (37). In 2004, >100 million prescriptions for statins were filled. The number of individuals using statins will continue to rise due to the rising incidence of cardiovascular disease and due to the ongoing research efforts into investigational uses of statins.


Figure 1
View larger version (11K):
[in this window]
[in a new window]
  		Fig. 1. Simplified scheme of mevalonate metabolism. HMG, 3-Hydroxy-3-methylgutaryl; CoA, coenzyme A.

 
The use of statins is relatively safe with few side effects. Myopathy is the most common side effect with symptoms ranging from fatigue, weakness, and pain to symptoms associated with rhabdomyolysis, which is a life-threatening condition (46). The development of statin-induced rhabdomyolysis is rare, occurring in ~0.1% of patients; however, the occurrence of less severe symptoms is underreported and may be 1–5% (46). Physical exercise appears to increase the likelihood for the development of myopathy in patients taking statins. It is thought that as many as 25% of statin users who exercise may experience muscle fatigue, weakness, aches, and cramping due to statin therapy and potentially dismissed by the patient and physician (46). The development of myopathy can impact daily living and quality of life by affecting the patient's ability to accomplish even simple tasks such as opening jars or may prevent participation in once enjoyable physical activities such as golf, tennis, or other forms of exercise. Currently, the only treatment for statin-induced myopathy is the discontinuation of statin use in affected patients, in which symptoms are most often reversible.

Identification of the mechanisms causing skeletal myopathy may lead to the development of effective preventative measures or treatments for patients who would benefit from statin therapy. The mechanisms that cause statin-induced myopathy have not been elucidated; however, research efforts suggest that apoptosis of myofibers may be a contributing factor. The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptosis will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.


   CELLULAR PROCESSES OF APOPTOSIS
TOP
 ABSTRACT
 CELLULAR PROCESSES OF APOPTOSIS
STATIN-INDUCED APOPTOSIS
 REFERENCES
 
Apoptosis is a cell suicide program that is highly regulated and executed via activation of specific signaling pathways. Hence, particular morphological, biochemical, and molecular events occur, such as DNA fragmentation, nuclear condensation, and formation of apoptotic bodies which are then engulfed by macrophages or neighboring cells without initiating an inflammatory response (20, 35, 36). Apoptosis allows for the death of a single cell without death or disruption to the surrounding tissue (20, 21). Apoptotic pathways can activate cysteine-dependent, aspartate-specific proteases (caspases), which are endoproteases, and are integral to the final execution of cell death (20, 21). There are 14 known mammalian caspases (i.e., caspase-1 through caspase-14), which participate in the apoptotic process depending on the stimulus and respective signaling pathway activated and/or cell type undergoing apoptosis. Caspases normally exist in an inactivated state, called procaspases, in the cytoplasm but can be activated by proteolytic cleavage (39). Initiation of apoptosis leads to the activation of a "caspase cascade," in which activation of "initiator" caspases (i.e., caspase-8, -9, and -12) cleave and activate "effector" caspases (i.e., caspase-3 and -7), which carry out the actual proteolytic events that result in cellular breakdown (39).

The mitochondrion plays a central role in regulating apoptosis (see Fig. 2). It can release cytochrome c into the cytosol, which then forms an "apoptosome" with Apaf-1, ATP, and procaspase-9. Once the apoptosome is formed, procaspase-9 can cleave and activate itself into caspase-9. Caspase-9 can then cleave and activate procaspase-3, leading to apoptosis. This process is highly regulated. The Bcl-2 family of proteins was the first described to affect the release of cytochrome c. This family consists of several proteins, which are antiapoptotic or proapoptotic. For example, Bcl-2 and Bcl-XL protect against cytochrome c release and are therefore anti-apoptotic while Bax, Bak, Bad, and Bid favor cytochrome c release and are therefore proapoptotic (1, 2, 15, 16, 21, 31). The ratio and interaction of the Bcl-2 family antiapoptotic and proapoptotic proteins determine the fate of cytochrome c release from the mitochondria. Often the Bcl-2/Bax ratio is used as an indicator of apoptotic potential where a high ratio protects against apoptosis and a low ratio favors apoptosis (2, 9, 34). Another regulatory protein that can regulate the release of cytochrome c release from the mitochondria is apoptosis repressor with card (ARC) (11). Upon stimulation, ARC can translocate from the cytosol to the mitochondrial membrane to inhibit the release of cytochrome c. Recent data show that ARC may prevent apoptosis by binding to Bax and interfering with its activation, which would ultimately protect against cytochrome c release (18). Another family of proteins that regulate the apoptotic process is the inhibitor of apoptosis protein (IAP) family. The IAPs (i.e., XIAP, cIAP-1, and cIAP-2) can bind to cleaved and activated caspase-9 and -3 to inhibit their enzyme activity and to prevent apoptosis (29). Finally, the mitochondria can release additional proteins, along with cytochrome c, to relieve the inhibition exerted by the IAPs so indeed apoptosis can be executed. These proteins include Smac/Diablo and Omi/HtrA2 (44, 47, 48).


Figure 2
View larger version (15K):
[in this window]
[in a new window]
  		Fig. 2. Mitochondrial-mediated apoptotic signaling. Cytochrome c (cyto c) release from the mitochondrion leads to formation of the apoptosome (cyto c, dATP, Apaf-1, and procaspase-9) and activation of procaspase-9. Active caspase-9 cleaves and activates procaspase-3, which leads to apoptosis. Bax and Bid favor cyto c release, while Bcl-2 and ARC inhibit cyto c release. Cellular inhibitors of apoptosis protein (cIAPs) inhibit apoptosis by inhibiting activation of procaspase-9 and -3 and/or inhibiting the activity of the cleaved caspases. Smac/Diablo and Omi/HtrA2 are released from the mitochondrion and inhibit cIAPs, relieving their inhibitory effect on apoptosis. Apoptosis-inducing factor and EndoG are also released from the mitochondrion and translocate to the nucleus where they induce DNA fragmentation in a caspase-independent manner. Arrows signify a stimulatory effect, and blunt lines signify an inhibitory effect. ARC, apoptosis repressor with card.

 
The mitochondrion can also play a role in inducing apoptosis in a caspase-independent manner. Upon stimulation, the mitochondrion can release proapoptotic proteins, such as apoptosis-inducing factor and endonuclease G, which translocate to the nucleus where they induce DNA fragmentation (6, 7, 23, 50)

Other apoptotic signaling pathways require an alternate initiator caspase to initiate the caspase cascade (i.e., caspase-8 and caspase-12). Receptor-mediated pathways can be activated by various ligands binding to its receptor and inducing apoptosis in an effector cell by the activation of procaspase-8, which can cleave and activate procaspase-3 to initiate the caspase cascade (43). Once apoptosis is initiated via caspase-8, the release of cytochrome c from the mitochondrion and activation of the mitochondrion-mediated signaling may occur, but is downstream from caspase-8 activation. Active caspase-8 can cleave Bid, which then stimulates Bax and Bak activity resulting in cytochrome c release (26, 50). Some cell types require activation of the mitochondrion-mediated signaling via Bid to execute apoptosis and others do not. Endoplasmic reticulum stress and calcium dyshomeostasis could also contribute to apoptosis via the activation of calpains and/or procaspase-12, which then leads to activation of procaspase-3 (10, 24, 38, 42).


   STATIN-INDUCED APOPTOSIS
TOP
 ABSTRACT
 CELLULAR PROCESSES OF APOPTOSIS
 STATIN-INDUCED APOPTOSIS
REFERENCES
 
It has been shown that statins can induce apoptosis in a variety of cell types, such as rheumatoid synovial cells, pericytes, smooth muscle cells, cardiac myocytes, and several types of cancer cells (3–5, 8, 12–14, 17, 27, 33, 49). It is thought that apoptosis of these above-mentioned cell types in diseased tissue may contribute to the pleiotropic benefits of statins. For example, apoptosis of transformed cells may prevent or slow the development of cancer (13). Statin-induced apoptosis of cardiac myocytes in some pathological states may attenuate cardiac hypertrophy and remodeling (8). However, statin-induced apoptosis of healthy skeletal myocytes may be a contributing factor causing myopathy, the most common side effect experienced by statin users (19, 30, 32, 40).

Evidence of apoptosis in statin-induced myopathy. Similar to the apoptosis-inducing effects of statins on many cell types, statins have also been shown to induce apoptosis in skeletal myocytes in vitro. It has recently been shown that various statins can induce apoptosis in skeletal myoblasts, myotubes, and in differentiated primary human skeletal muscle cells, most often in a concentration-dependent manner (19, 30, 32, 40). The data support that statin-induced apoptosis in skeletal muscle cells may be mitochondrial-mediated as shown by an increase in active caspase-9 and caspase-3 (19, 40). Sacher et al. (40) show that Bax translocates to the mitochondria in response to statin treatment, which may lead to the release of cytochrome c and activation of the mitochondrial-mediated apoptotic signaling pathway. Addition of mevalonate prevents statin-induced apoptosis and caspase-3 activation (19, 40). These results suggest that the depletion of downstream products of mevalonate synthesis induces apoptosis of skeletal muscle cells in a mitochondrial-mediated manner in vitro. These results are consistent with in vitro data generated in non-skeletal muscle cell lines, which also support a mitochondrial-mediated mechanism of statin-induced apoptosis. It has been shown in vascular smooth muscle cells that apoptosis induced by statins is associated with suppressed levels of Bcl-2, whereas Bax expression was not altered, and induced activation of caspase-9. Coincubation of cells with a caspase inhibitor significantly inhibited apoptosis (3). Statin-induced apoptosis of anaplastic thyroid cancer cells was associated with cytochrome c release from the mitochondria and an increase in activity of caspases-2, -3, and -9. Activities of caspases-1 and -8 were not affected (49). Therefore, statin-induced apoptosis is likely executed via a mitochondrial-mediated mechanism involving a decrease in the Bcl-2/Bax ratio leading to cytochrome c release and activation of caspase-9, followed by activation of caspase-3.

Although it is clear the statins induce apoptosis in vitro, it is not as clear whether statins induce skeletal muscle apoptosis in vivo. Only one study to date has been published which report the effects of statins on apoptotic markers in skeletal muscle in vivo (41). Seachrist et al. (41) report cervistatin-induced muscle damage after 14 days of administration to female rats. Protein levels of cleaved caspase-3 were only measured 24-h post dose and did not differ from controls. DNA fragmentation or other characteristic markers of apoptosis were not assessed. The data, although limited, suggest that skeletal muscle apoptosis may not occur in vivo. However, further in vivo studies will delineate if apoptosis may occur at later time points beyond 24 h and coincide with the appearance of muscle degeneration.

Mechanism of apoptosis in statin-induced myopathy. Despite ongoing research efforts, the underlying pathology of statin induced myopathy remains largely speculative. Although the primary clinical use of statins is to lower cholesterol levels by inhibiting de novo cholesterol synthesis, evidence supports that a decreased cholesterol level likely is not a significant factor contributing to myopathy. Experiments show that the inhibition of squalene synthase, an enzyme downstream of HMG-CoA reductase in the cholesterol biosynthetic pathway, does not cause myotoxicity (19). This suggests that myotoxicity due to HMG-CoA reductase inhibition by statins is not due to decreased synthesis of cholesterol but rather to suppressed synthesis of alternative downstream products of mevalonate metabolism, such as the isoprenoids.

Indeed, it has been shown in several cell types, including skeletal muscle cells, that depletion of isoprenoids are responsible for the induction of apoptosis (3, 8, 13, 14, 17, 19, 27, 30, 33, 49). Isoprenoid intermediates serve as important lipid moieties for the posttranslational modifications of membrane-associated proteins such as Ras, Rho, and Rac (25, 28). Isoprenylation, farnesylation and geranylgeranylation, of these proteins regulate their translocation to the plasma membrane and/or activity (25, 28). For example, farnesylation of Ras is required for its translocation from the cytoplasm to the plasma membrane where it becomes activated and geranylgeranylation of Rho is required for its translocation to the plasma membrane (27). Isoprenoids are also required for the synthesis of ubiquinone, a component of the electron transport chain.

Research efforts have been focused on whether apoptosis induced by isoprenoid depletion is a result of impaired ubiquinone synthesis, farnesylation, and/or geranylgeranylation of signaling proteins. There is not sufficient evidence to support that statin induced apoptosis is due to ubiquinone depletion (19, 22, 45). Johnson et al. (19) found no correlation between statin-induced apoptosis of rat and human myotubes and ubiquinone levels. Moreover, coadministration of mevalonate with cervastatin prevented apoptosis but did not have an effect on concentration of ubiquinone. Several in vitro studies have shown that coadministration of geranylgeranyl pyrophosphate with statins prevented or decreased the occurrence of apoptosis in various cell types, while farnesyl pyrophosphate had little or no effect (8, 13, 19, 33, 49). It has been further shown that inhibition of geranylgeranylation and the RhoA pathway, using a geranylgeranyltransferase inhibitor, in human endothelial cells induced apoptosis while inhibition of farnesylation did not (27). Similar results have been shown in anaplastic thyroid cancer cells treated with statin. Statin treatment of these cells is associated with a dose-dependent decrease in the translocation of RhoA and Rac1, but not Ras, from the cytosol to the membrane (49). Thus, in some cell types, statin-induced apoptosis may be stimulated by inhibition of geranylgeranylation while the inhibition of farnesylation is less important. However, statin-induced apoptosis in L6 rat myoblasts, an undifferentiated cell type, has been shown to be associated with depletion of membrane-farnesylated Ras depletion, rather than geranylgeranylated Rho (30). Also, statin-induced apoptosis of vascular smooth muscle cells is rescued by geranylgeranyl pyrophosphate or farnesyl pyrophosphate, suggesting that both cellular processes are important for cell survival (17). Taken together, these results suggest that statin-induced apoptosis is likely not due to depletion of ubiquinone but rather due to the depletion of geranylgeranylated proteins or farnesylated proteins, which may be dependent on cell type or the state of differentiation.

Statin-induced apoptosis in skeletal myoblasts and myotubes has also been associated with elevated levels of cytosolic calcium (32, 40). It has been shown that statins induce the phosphorylation of tyrosine, which leads to an increase in cytosolic calcium, resulting in apoptosis (32). It is speculated that the alteration in isoprenoid synthesis with statin therapy is responsible for the tyrosine phosphorylation and stimulation of pathways causing a rise in cytosolic calcium. Sacher et al. (40) have shown that the elevated calcium levels in response to statins activate calpain, which in turn leads to apoptosis via the translocation of Bax to the mitochondria and activation of caspase-9 and caspase-3. Inhibition of the mitochondrial transition pore, in which opening is required for cytochrome c release and thought to be regulated by Bax, prevented apoptosis and activation of caspase-9 and caspase-3. Further experimentation showed that chelation of calcium completely prevented calpain, caspase-9, and caspase-3 activation (40). Also, coadministration of mevalonate with the statin attenuated the rise in cytosolic calcium levels, although did not completely prevent it (40). Taken together, statin-induced apoptosis is largely in part due to the depletion of isoprenoids, which in turn can decrease protein geranylgeranylation and/or farnesylation, which may lead to elevated levels of cytosolic calcium and activation of calpain and the mitochondrial-mediated apoptotic signaling cascade (see Fig. 3).


Figure 3
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 3. Hypothesized scheme of statin-induced apoptosis in skeletal muscle cells. Isoprenoid depletion, which can lead to the lack of geranylgeranylation and/or farnesylation of proteins, may lead to an increase in cytosolic calcium levels which in turn activates calpain. Activation of calpain leads to Bax translocation to the mitochondria causing cytochrome c release via the mitochondrial transition pore. Release of cytochrome c leads to the activation of caspase-9, which cleaves and activates caspase-3. MTP, mitochondrial transition pore.

 
In conclusion, statins are the most effective lipid lowering drugs on the market and are used by >100 million people worldwide. Statins also have pleiotropic effects that may extend the use to the treatment and prevention of other disease states, such as cancer. Fortunately, statins have few side effects. The most common side effect is skeletal myopathy with symptoms, ranging from fatigue and pain to life-threatening rhabdomyolysis. The only effective treatment for statin-induced myopathy is to discontinue use of the drug. Elucidation of the mechanisms behind the myopathy may lead to treatments that would prevent the myopathy while patients could continue use of the statin. Apoptosis of myofibers may be a contributing mechanism. Evidence supports that statin-induced apoptosis is likely stimulated by isoprenoid depletion, resulting in a decrease of protein geranylgeranylation and/or farnesylation, which, in turn, may lead to elevated levels of cytosolic calcium and activation of mitochondrial-mediated apoptotic signaling.


   FOOTNOTES
 

Address for reprint requests and other correspondence: A. J. Dirks, School of Pharmacy, Wingate Univ., 316 N. Main St., Wingate, NC 28174 (e-mail: adirks{at}wingate.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 CELLULAR PROCESSES OF APOPTOSIS
 STATIN-INDUCED APOPTOSIS
 REFERENCES
 
1. Adams JM and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326, 1998.[Abstract/Free Full Text]

2. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, and Martinou JC. Inhibition of Bax channel-forming activity by Bcl-2. Science 277: 370–372, 1997.[Abstract/Free Full Text]

3. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, and Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161: 17–26, 2002.[CrossRef][Web of Science][Medline]

4. Boucher K, Siegel CS, Sharma P, Hauschka PV, and Solomon KR. HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc Res 71: 91–102, 2006.[CrossRef][Web of Science][Medline]

5. Cafforio P, Dammacco F, Gernone A, and Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883–891, 2005.[Abstract/Free Full Text]

6. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, and Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 476: 118–123, 2000.[CrossRef][Web of Science][Medline]

7. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, and Kroemer G. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 14: 729–739, 2000.[Abstract/Free Full Text]

8. Demyanets S, Kaun C, Pfaffenberger S, Hohensinner PJ, Rega G, Pammer J, Maurer G, Huber K, and Wojta J. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol 71: 1324–1330, 2006.[CrossRef][Web of Science][Medline]

9. Dirks A and Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 282: R519–R527, 2002.[Abstract/Free Full Text]

10. Dirks AJ and Leeuwenburgh C. Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med 36: 27–39, 2004.[CrossRef][Web of Science][Medline]

11. Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC III, and Nunez G. ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ Res 85: e70–e77, 1999.[Web of Science][Medline]

12. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Current Drug Targets Cardiovasc Haematol Disord 5: 135–144, 2005.

13. Fromigue O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P, and Marie PJ. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. In Press.

14. Graaf MR, Richel DJ, van Noorden CJ, and Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609–641, 2004.[CrossRef][Web of Science][Medline]

15. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1–4, 2000.[CrossRef][Web of Science][Medline]

16. Gross A, McDonnell JM, and Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899–1911, 1999.[Free Full Text]

17. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, and Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490–500, 1998.[Abstract/Free Full Text]

18. Gustafsson AB, Tsai JG, Logue SE, Crow MT, and Gottlieb RA. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J Biol Chem 279: 21233–21238, 2004.[Abstract/Free Full Text]

19. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, and Umbenhauer DR. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200: 237–250, 2004.[CrossRef][Web of Science][Medline]

20. Kerr JF, Wyllie AH, and Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257, 1972.[Web of Science][Medline]

21. Kluck RM, Bossy-Wetzel E, Green DR, and Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132–1136, 1997.[Abstract/Free Full Text]

22. Koumis T, Nathan JP, Rosenberg JM, and Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? Am J Health Syst Pharm 61: 515–519, 2004.[Free Full Text]

23. Kroemer G. B709 mitochondrial control of cell death. Sci World J 1: 48, 2001.

24. Larner SF, Hayes RL, McKinsey DM, Pike BR, and Wang KK. Increased expression and processing of caspase-12 after traumatic brain injury in rats. J Neurochem 88: 78–90, 2004.[Web of Science][Medline]

25. Laufs U and Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 5: 372–378, 2003.[Medline]

26. Li H, Zhu H, Xu CJ, and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501, 1998.[CrossRef][Web of Science][Medline]

27. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, and Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277: 15309–15316, 2002.[Abstract/Free Full Text]

28. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285–288, 2002.[CrossRef][Web of Science][Medline]

29. Liston P, Young SS, Mackenzie AE, and Korneluk RG. Life and death decisions: the role of the IAPs in modulating programmed cell death. Apoptosis 2: 423–441, 1997.[CrossRef][Web of Science][Medline]

30. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, Nakabayashi T, and Matsuyama K. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 57: 1475–1484, 2005.[CrossRef][Web of Science][Medline]

31. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, and Fesik SW. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381: 335–341, 1996.[CrossRef][Medline]

32. Mutoh T, Kumano T, Nakagawa H, and Kuriyama M. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett 444: 85–89, 1999.[CrossRef][Web of Science][Medline]

33. Nagashima T, Okazaki H, Yudoh K, Matsuno H, and Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54: 579–586, 2006.[CrossRef][Web of Science][Medline]

34. Phaneuf S and Leeuwenburgh C. Cytochrome c release from mitochondria in the aging heart: a possible mechanism for apoptosis with age. Am J Physiol Regul Integr Comp Physiol 282: R423–R430, 2002.[Abstract/Free Full Text]

35. Pollack M and Leeuwenburgh C. Apoptosis and aging: role of the mitochondria. J Gerontol A Biol Sci Med Sci 56: B475–482, 2001.[Abstract/Free Full Text]

36. Pollack M, Phaneuf S, Dirks A, and Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann NY Acad Sci 959: 93–107, 2002.[CrossRef][Web of Science][Medline]

37. Raja SG and Dreyfus GD. Statins: much more than just a lipid-lowering therapy. Indian Heart J 56: 204–209, 2004.[Medline]

38. Rao RV, Hermel E, Castro-Obregon S, del Rio G, Ellerby LM, Ellerby HM, and Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 276: 33869–33874, 2001.[Abstract/Free Full Text]

39. Renatus M, Stennicke HR, Scott FL, Liddington RC, and Salvesen GS. Dimer formation drives the activation of the cell death protease caspase 9. Proc Natl Acad Sci USA 98: 14250–14255, 2001.[Abstract/Free Full Text]

40. Sacher J, Weigl L, Werner M, Szegedi C, and Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 314: 1032–1041, 2005.[Abstract/Free Full Text]

41. Seachrist JL, Loi CM, Evans MG, Criswell KA, and Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci 88: 551–561, 2005.[Abstract/Free Full Text]

42. Shibata M, Hattori H, Sasaki T, Gotoh J, Hamada J, and Fukuuchi Y. Activation of caspase-12 by endoplasmic reticulum stress induced by transient middle cerebral artery occlusion in mice. Neuroscience 118: 491–499, 2003.[CrossRef][Web of Science][Medline]

43. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, and Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274: 5053–5060, 1999.[Abstract/Free Full Text]

44. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, and Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8: 613–621, 2001.[CrossRef][Web of Science][Medline]

45. Thompson PD, Clarkson PM, and Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 97: S69–76, 2006.[CrossRef]

46. Tomlinson SS and Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 85: 459–465, 2005.[Free Full Text]

47. Vaux DL and Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 304: 499–504, 2003.[CrossRef][Web of Science][Medline]

48. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129–1132, 1997.[Abstract/Free Full Text]

49. Zhong WB, Wang CY, Chang TC, and Lee WS. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144: 3852–3859, 2003.[Abstract/Free Full Text]

50. Zimmermann KC, Bonzon C, and Green DR. The machinery of programmed cell death. Pharmacol Ther 92: 57–70, 2001.[CrossRef][Web of Science][Medline]




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
V. Prinz and M. Endres
The Acute (Cerebro)Vascular Effects of Statins
Anesth. Analg., August 1, 2009; 109(2): 572 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
G. W. Allison, R. J. Perla, P. P. Belliveau, and S. M. Angelis
Elevated creatine phosphokinase levels associated with linezolid therapy
Am. J. Health Syst. Pharm., June 15, 2009; 66(12): 1097 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 VASC ENDOVASCULAR SURGHome page
L. Mascitelli, F. Pezzetta, M. R. Goldstein, and R. H. Samson
Questioning the Safety of Life-long Statin Therapy in Patients With Peripheral Arterial Disease
Vascular and Endovascular Surgery, February 1, 2009; 43(1): 109 - 111.
[PDF]

Home page
 BMJHome page
M. Kendrick
Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No
BMJ, May 12, 2007; 334(7601): 983 - 983.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/C1208    most recent
00226.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dirks, A. J.
Right arrow Articles by Jones, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dirks, A. J.
Right arrow Articles by Jones, K. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.